Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
Conclusions. In Thailand, denosumab offers a cost-effective osteoporosis treatment option versus no pharmacologic treatment in postmenopausal women at high risk of fracture. PMID: 32063082 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 20, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
CONCLUSIONS: Increased mt-sDNA utilization leads to fewer colonoscopies, less adverse events and lower overall costs for both IDNs and payers, reducing overall screening program costs and increasing the number of cancers detected while maintaining screening adherence rates over 10 years. PMID: 32063100 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 20, 2020 Category: Health Management Tags: J Med Econ Source Type: research

A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
CONCLUSIONS: SIR-Spheres Y-90 resin microspheres resulted in cost savings relative to TKIs in the treatment of unresectable HCC in all four country settings, while increasing the proportion of patients who become eligible for treatments with curative intent. PMID: 32067534 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 20, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.
Conclusions: In conclusion, conducting clinical-trials by pharmaceutical industry - beside its importance in its own domain - results in tangible benefits and positive macroeconomic impact that contribute to the sustainability of the Austrian health-care-system by complementing its limited resources. Furthermore, it is a non-negligible factor in locational and industrial policy. PMID: 32046538 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 14, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
CONCLUSION: This study concluded that 6-month trastuzumab is a cost-effective option when compared to 1-year trastuzumab in patients with HER2 + ve ABC in Egypt. Our findings provide health care decision makers with additional insights to best allocate available resources concurrently with the improvement of the Egyptian patient's outcomes. PMID: 32011199 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 7, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Patients' preferences for the treatment of anxiety and depressive disorders: A systematic review of discrete choice experiments.
Conclusion In this systematic review, heterogeneous results were observed regarding the inclusion and framing of different attributes across studies. Overall, patients considered process and cost attributes to be more important than outcome attributes. Outcomes and process are important for patients, and thus clinicians should be particularly aware of this and take patients' preferences into account, although the attribute importance may depend on chosen attributes and related levels. PMID: 32011209 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 7, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
Conclusions: Secondary prevention with clopidogrel is an attractive cost-effective option compared with aspirin for high risk patients with established PAD from the perspective of the national healthcare system in Chinese settings. PMID: 31999196 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: A real-world data analysis.
Conclusions: CDI and rCDI are associated with substantial healthcare resource utilization and direct medical costs. Timing of recurrences can be predictable, providing a window of opportunity for interventions. Prevention of multiple rCDI appears essential to reduce healthcare costs. PMID: 31999199 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Real world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin.
Authors: Blaylock B, Epstein J, Stickler P Abstract BACKGROUND & AIMS: Patients with acute intermittent porphyria (AIP) may suffer from acute non-specific attacks that often result in hospitalizations or emergency room visits. Prior to the recent approval of givosiran (November 2019), hemin was the only FDA-approved therapy for AIP attacks in the US. Our aim was to estimate the annual healthcare utilization and expenditures for AIP patients treated with hemin using real-world data. METHODS: Patients with ≥1 hemin claim and confirmed AIP diagnosis - 1 inpatient claim or 2 outpatient claims ≥30 days apa...
Source: Journal of Medical Economics - February 1, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: A matching-adjusted indirect comparative analysis.
Authors: Wu JJ, Hansen JB, Patel DS, Nyholm N, Veverka KA, Swensen AR Abstract Background: The fixed-dose combination foam formulation of calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) has demonstrated efficacy and a favorable safety profile for the treatment of plaque psoriasis. Recently, a topical lotion of the combination of halobetasol 0.01% plus tazarotene 0.045% (HP/TAZ) was approved for treating adult plaque psoriasis. Currently, no head-to-head studies have compared Cal/BD foam with HP/TAZ lotion.Objective: Compare the effectiveness and drug incremental cost per responder (ICPR) of Cal...
Source: Journal of Medical Economics - January 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada.
The objective of this study was to assess the cost-effectiveness of abobotulinumtoxinA vs. onabotulinumtoxinA in the treatment of PLL spasticity in Canada. METHODS: A probabilistic Markov cohort model with a 2-year time horizon was developed, with health states defined by response to therapy, as characterized by the goal attainment scale (GAS). Based on randomized controlled trial evidence, response to therapy was similar or higher for abobotulinumtoxinA relative to onabotulinumtoxinA; uncertainty was incorporated into model parameters, however, as the two therapies have not been compared head-to-head. Canadian resourc...
Source: Journal of Medical Economics - January 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Evaluation of four disease management programs: Evidence from Blue Cross Blue Shield of Louisiana.
Conclusions: DM programs implemented to control diabetes, CHD/HTN, CHF/CKD, and asthma/COPD are cost-effective and show some evidence of improved clinical outcomes. PMID: 31990232 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: A cost of control analysis.
Authors: B Hansen B, Nuhoho S, Ali SN, Dang-Tan T, Valentine WJ, Malkin S, Hunt B Abstract Aims: The efficacy and safety of oral semaglutide, the first glucagon-like peptide-1 (GLP-1) receptor agonist developed for oral administration for the treatment of type 2 diabetes, was evaluated in the PIONEER clinical trial program, and a recently published network meta-analysis allowed comparison with further injectable GLP-1 receptor agonists. The present study aimed to assess the short-term cost effectiveness of oral semaglutide 14 mg versus subcutaneous once-weekly dulaglutide 1.5 mg, once-weekly exenatide...
Source: Journal of Medical Economics - January 29, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review.
Conclusions: CU modeling for RA increasingly reflects real-world conditions and patient experiences which are anticipated to provide better information in the assessment of health technologies. Future CU models in RA should consider applying the observed advances in modeling choices to optimize their CU predictions and simulation of real-world outcomes. PMID: 31971039 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 25, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.
Conclusions: Valoctocogene roxaparvovec was found to be cost-saving-on average by about $6.8 million per patient-and more effective than prophylactic therapy for treatment of hemophilia A. The comparative benefit of gene therapy was observed across a broad range of simulated patients that were representative of the real-world severe hemophilia A population. PMID: 31971453 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 25, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of mirogabalin for the treatment of post-herpetic neuralgia in Taiwan.
Authors: Ye X, Gray E, Wang YF, Wang SJ Abstract Objectives: To assess the cost-effectiveness of mirogabalin versus no treatment or pregabalin in patients with post-herpetic neuralgia (PHN) from a third-party perspective in Taiwan.Methods: A Markov model, which was developed with 2-week cycles and 1-year time horizon from the Taiwanese National Health Insurance Administration perspective, consisted of three health states: 'mild', 'moderate' and 'severe' pain. Average daily pain score (ADPS) was assessed at the end of each cycle. Patients either remained in, or transitioned from, their assigned health state to a dif...
Source: Journal of Medical Economics - January 25, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Authors: Sicras-Mainar A, Capel M, Navarro-Artieda R, Nuevo J, Orellana M, Resler G Abstract Objective: We determined the percentage of patients with severe asthma and exacerbations and evaluated the costs of the disease based on blood eosinophil counts.Methods: A retrospective observational study based on the review of medical records in Spain was carried out. Patients ≥18 years of age requiring care during the years 2014-2015; diagnosed with asthma with at least 2 years of continuous records (at least one year prior to the index date defined as the first asthma medication prescription and at least one year aft...
Source: Journal of Medical Economics - January 22, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Treatment patterns and direct medical costs of metastatic colorectal cancer patients: A retrospective study of electronic medical records from urban China.
Conclusions: Before 2017, mCRC patients in China did not receive the maximum benefits of precision medicine breakthroughs. Reduced treatment cycles and increased costs per cycle from first- to third-line suggested poor healthcare resource utilization. With earlier initiation and more treatment cycles, targeted biologics may better demonstrate their effectiveness among Chinese patients. Our findings reflected the urgent need to increase drug accessibility in China before 2017 and underscore that including innovative biologics into Chinese health insurance plans can reduce patients' economic burden and improve the management...
Source: Journal of Medical Economics - January 19, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Conclusion: Atezolizumab is more efficient and more costly than docetaxel in the 2nd line treatment of NSCLC of stage IIIB or IV, in France, with results consistent to previous French authorities' evaluation of immunotherapies in similar indication. Lastly, atezolizumab is a cost saving alternative to nivolumab, based on list price. PMID: 31951770 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 19, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Conclusions: Treatment of highly active RRMS with cladribine tablets was less costly and more effective than treatment with fingolimod. Hence, it is a dominant strategy in the Portuguese setting. No conclusions can be drawn from the present study regarding other treatment options, in particular natalizumab and alemtuzumab. PMID: 31951777 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 19, 2020 Category: Health Management Tags: J Med Econ Source Type: research

The economic impact of clinically significant tricuspid regurgitation in a large, administrative claims database.
Conclusion: The presence of clinically significant TR is associated with an increase in healthcare utilization and expenditures, irrespective of the presence of HF. PMID: 31952454 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 19, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Health technology assessment in Japan: a work in progress.
Discussion: Japan's new HTA program is a first step toward development of a universal healthcare system that can be sustainable for many years into the future. Currently, Japan's HTA program requires provision of incremental cost-effectiveness ratios (ICERs) as evidence, with quality-adjusted life years as the preferred measure. Prices can be adjusted both upward and downward according to the degree of the ICER estimate. Japan is the first country to have adopted an algorithmic method for 'ICER-based' pricing; however, HTA measures that extend beyond a single ICER estimate are needed to take full advantage of HTA in the fu...
Source: Journal of Medical Economics - January 18, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Conclusion: These results suggest that, at a willingness-to-pay threshold of $150,000 per QALY, nivolumab is a cost-effective option for therapy of SCCHN in the US. PMID: 31928375 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 15, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.
Conclusions: Due to the high prevalence of CAD and/or PAD and the associated high unit costs, this population generates a significant economic burden, which is higher among patients with PAD and in those presenting simultaneously with both conditions. PMID: 31928390 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 15, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of FOLFIRI  + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.
Conclusions: Based on our analyses, FOLFIRI-cet is cost-effective compared with FOLFIRI-bev in patients with RAS wt mCRC, with ICERs well below willingness-to-pay thresholds for diseases with a high burden. PMID: 31903807 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 8, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
Conclusions: The population of UK RRMS patients may experience overall health gains if patient preferences are better incorporated into prescribing practices. PMID: 31903813 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - January 8, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
Conclusion: This study provides an accurate assessment of the main lymphoma subtypes related cost with high magnitude of details in a real-world setting. We underline where potential cost saving could be realized via the use of biosimilar medication, and where lymphoma management could be improved with the early management of adverse events.KEY POINTSThis is one of the first studies which assess the additional cost of lymphoma in Europe, according the main sub-types of lymphoma and with real-world database.The additional monthly cost due to HL, FL and DLBCL patients were respectively €5,188, €3,242 and €7,65...
Source: Journal of Medical Economics - December 27, 2019 Category: Health Management Tags: J Med Econ Source Type: research

A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
Conclusion: The use of apremilast as a first option before the use of biologic agents may represent a cost-effective treatment strategy for patients with PsA who fail to respond to, or are intolerant to, previous DMARD therapy. In addition, based on a budget impact perspective, the use of apremilast may lead to cost savings to the Italian healthcare system. PMID: 31856609 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare utilization and cost burden among women with endometriosis by opioid prescription status in the first year after diagnosis: a retrospective claims database analysis.
Authors: As-Sanie S, Soliman AM, Evans K, Erpelding N, Lanier R, Katz NP Abstract AIMS: Opioids do not represent standard therapy for endometriosis; however, women with endometriosis are frequently prescribed an opioid to manage related abdominal or pelvic pain. The aim of this study was to evaluate the impact of opioid use on endometriosis-related economic and healthcare burden in the United States. MATERIALS AND METHODS: We performed a retrospective, propensity-matched cohort analysis of the Truven MarketScan Commercial database from January 1, 2011 to December 31, 2016. Eligible women had at least 1 inpatien...
Source: Journal of Medical Economics - December 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

A population-based study of the humanistic burden among cancer patients in Japan.
This study broadly examined the cancer burden in terms of; Health Related Quality of Life (HRQoL), work productivity and activity impairment (WPAI), stress-related comorbidities, and indirect costs in patients diagnosed with i) any type of cancer, ii) breast cancer, iii) colorectal cancer, compared to controls without cancer.Materials and methods: This cross-sectional study used data from the 2017 Japan National Health and Wellness Survey (NHWS). Patient outcomes included self-reported stress-related comorbidities, HRQoL assessed by Short Form 12-item Health Survey and EuroQoL 5-dimension scale (EQ-5D), and work productivi...
Source: Journal of Medical Economics - December 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
Conclusion Although ramucirumab was associated with prolonged survival for patients with advanced hepatocellular carcinoma who progressed on sorafenib treatment with an AFP of at least 400 ng/ml, it is not a cost-effective treatment from a United States payer perspective. PMID: 31856618 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting.
Conclusion: These models proved to be robust to variation in parameters and it suggested that the use of apremilast would lead to savings to the Italian healthcare system with potential benefits in terms of patients' quality of life. PMID: 31856619 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Living with ulcerative colitis in Germany: A retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Conclusions: These data suggest that control with current biologics is suboptimal. Further treatment options that provide sustained steroid-free remission for this patient population without the need for dose escalations or concomitant therapies may be warranted. PMID: 31858853 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 22, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: Evaluation of a machine learning risk prediction algorithm.
Conclusions: Targeted screening using a ML risk prediction algorithm has the potential to enhance the clinical and cost-effectiveness of AF screening, improving health outcomes through efficient use of limited healthcare resources. PMID: 31855091 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 20, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
Conclusions-AEs increase the economic burden and therapy discontinuation among nmPC patients receiving secondary hormonal therapies subsequent to ADTs. These patients should be carefully evaluated for AEs to reduce therapy discontinuation, HCRU, and direct medical costs. PMID: 31835965 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 16, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models.
CONCLUSION: Using an example of GART for HIV, this study demonstrates comparative analysis of previously published cost effectiveness models yields critical information which can be used to inform the structure and specifications of new models. PMID: 31835974 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 16, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
Conclusion: Recurrent VTE among cancer patients is associated with significant HRU and healthcare costs, notably hospitalizations. Strategies to reduce VTE recurrence in patients with cancer can contribute to reducing healthcare cost. PMID: 31818164 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
Conclusions: For patients with T2DM and established cardiovascular disease in this real-world study, treatment with canagliflozin was associated with lower HHF costs and all-cause healthcare costs compared with treatment with non-SGLT2i AHAs. PMID: 31801393 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 6, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The Burden Associated with Thrombocytopenia and Platelet Transfusions among Patients with Chronic Liver Disease.
Authors: Elsaid MI, Rustgi VK, Loo N, Aggarwal K, Li-McLeod J, Niu X, Poordad F Abstract Background: Thrombocytopenia (TCP), a common complication of chronic liver disease (CLD), can cause uncontrolled bleeding during procedures. As such, CLD patients with TCP and platelet counts
Source: Journal of Medical Economics - November 30, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
Authors: Shih TM, Sail KR, Jalundhwala YJ, Sullivan J, van Eijndhoven E, Zadikoff C, Marshall TS, Lakdawalla DN Abstract Aims: To estimate the relationship between functional status (FS) impairment and nursing home admission (NHA) risk in Parkinson's disease (PD) patients, and quantify the effect of advanced PD (APD) treatment on NHA risk relative to standard of care (SoC).Materials and methods: PD patients were identified in the Medicare Current Beneficiary Survey (MCBS) (1992-2010). A working definition based on the literature and clinical expert input determined APD status. A logit model estimated the relationsh...
Source: Journal of Medical Economics - November 30, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China.
CONCLUSIONS: Olmesartan/amlodipine fixed-dose combination confers better health outcomes and costs less compared with olmesartan and amlodipine free combination and valsartan/amlodipine fixed-dose combination and is cost-effective compared with amlodipine for hypertension treatment in China. PMID: 31782677 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 30, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Perioperative inhaled corticosteroids treatment is associated with decreased length-of-stay and direct medical costs in high-respiratory-risk surgeries.
Conclusions: Perioperative ICS treatment was associated with decreased LOS and lower costs for patients undergoing high-respiratory-risk surgeries in China. PMID: 31782678 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 30, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: An examination of the commercial and Medicaid populations.
Conclusions: Mean overall healthcare costs were similar between CPP patients treated with leuprolide and those treated with histrelin. Medicaid patients generally received less testing and were less likely to receive specialist care. Patients treated with histrelin had fewer office visits but also had a shorter overall treatment. PMID: 31766907 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 27, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab vs. ipilimumab plus nivolumab in US academic centers.
Conclusions: PEMBRO patients had significantly lower probability of hospitalization through 12 months vs IPI + NIVO. Probability of ED visits did not differ. PMID: 31750751 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 23, 2019 Category: Health Management Tags: J Med Econ Source Type: research

The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD.
CONCLUSIONS: This model demonstrated favorable short- and long-term clinical benefits associated with the use of ERC in patients with CKD Stage 3 and 4 with SHPT and VDI, suggesting ERC may be cost-effective from the Medicare perspective compared to paricalcitol. PMID: 31726882 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 16, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain.
Conclusions Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs. PMID: 31686550 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
This study evaluated healthcare resource utilization (HCRU), and direct costs among severe aplastic anemia (SAA) patients treated with eltrombopag (EPAG) using US claims data.Methods: This retrospective, real-world claims database study identified SAA patients aged ≥2 years treated with EPAG who initiated any SAA treatment between July 1, 2014 and December 31, 2017 (identification period) using the Truven MarketScan® databases. A subset of 82 patients treated with EPAG during the identification period were evaluated for all-cause and SAA-related HCRU and direct costs as well as blood transfusion one month before EPA...
Source: Journal of Medical Economics - November 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.
Conclusion. Rivaroxaban is cost-effective against warfarin for stroke prevention in Japanese patients with NVAF, giving the payer WTP of 5,000,000 JPY. PMID: 31687870 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 7, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database.
Conclusions: Total medical costs for MM have remained stable since 2010. MM drug costs increased, but costs for other care decreased after the launch of lenalidomide in 2010 and other drugs in 2015 and later. More detailed research is required to confirm whether the launch of novel drugs caused the changes in medical costs. PMID: 31682533 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 6, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a united states based retrospective claims database analysis.
Conclusions: Among post-MI and post-stroke patients, inadequate MDD care was associated with a significantly higher economic burden. PMID: 31665949 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 2, 2019 Category: Health Management Tags: J Med Econ Source Type: research